Insulin Therapy and Weight Gain
Insulin is the most effective glucose-lowering medicine but commonly adds 2 to 4 kilograms in the first year, through retained calories and defensive eating after low blood sugar.
Plain English
Patient-Friendly Explanation
Insulin is the most effective medicine for lowering blood sugar, but it commonly causes weight gain, typically 2 to 4 kilograms in the first year and more with higher doses. There are two main reasons. Insulin helps move glucose into cells instead of letting it leave in the urine, so calories that were previously lost are now retained, and it can cause low blood sugar, which drives hunger and defensive eating. Weight gain is not a reason to refuse insulin when it is genuinely needed, because untreated high blood sugar causes far more harm. The aim instead is the lowest effective dose, fewer low sugars, and combining insulin with other medicines and lifestyle measures that limit weight gain.
Medical
Clinical Definition
Weight gain with insulin therapy results from several mechanisms: reversal of glycosuria, where each gram of retained glucose represents about 4 kilocalories, so patients with poor control before treatment may gain several kilograms from reduced calorie loss alone; reduced hepatic glucose output with suppression of ketogenesis and lipolysis; an anabolic effect on adipose tissue; and over-treatment of hypoglycaemia through defensive snacking, which is amplified by fear of nocturnal low blood sugar. Typical weight gain is roughly 2 to 4 kilograms over the first 6 to 12 months and is greater with higher doses, with basal-bolus regimens and with aggressive glycaemic targets, while it is smaller with once-daily basal insulin using a conservative titration strategy; trial data from intensive glucose control show the gain is dose-dependent and largely confined to the first year. Management includes using the lowest effective dose, combining insulin with metformin, which mitigates weight gain, and with GLP-1 receptor agonists or dual GIP and GLP-1 receptor agonists, which reliably offset it, and considering SGLT2 inhibitors where appropriate; structured education on recognising and treating hypoglycaemia without over-treating it is essential, as is distinguishing genuine hunger from rebound eating after a low. Insulin remains indicated for type 1 diabetes, for marked hyperglycaemia with catabolic features, and when other agents are insufficient, and the choice between insulin-first and incretin-first strategies should weigh glycaemic need, weight, hypoglycaemia risk and cost together with the patient.
Key Insight
Why It Matters
Patients who need insulin often worry most about gaining weight, and that fear delays treatment that protects their eyes, kidneys and nerves. Combining insulin with glucose-lowering medicines that are weight-neutral or weight-reducing, and titrating carefully to avoid low sugars, usually keeps the scale stable.
Sources
Reviewed against standard medical references.
Medically reviewed by
Family Physician & Registered Acupuncturist, Accord Medical Clinic. MBBS (NUS), Graduate Diploma in Family Medicine (NUS), Graduate Diploma in Acupuncture (Singapore College of TCM).
Last reviewed: September 2026
This page is general health education, not medical advice. Whether any treatment is appropriate for you is a decision made in consultation after assessment.
